Galectin Therapeutics Inc.

GALT · Nasdaq · United States

Share price · GALT

$2.98-0.54 (-15.34%) 3M

close as of 2026-11-18 · 24h delayed · vol 234K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GALT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+10.2%
  2. 13 Aug 2026+12.4%
  3. 14 Jul 2026+16.1%
  4. 13 Jul 2026+13.3%
  5. 26 Jun 2026+18.0%
  6. 24 Jun 2026+25.6%
  7. 23 Jun 2026+11.4%
  8. 26 May 2026+11.6%
  9. 21 May 2026+14.0%
  10. 16 Apr 2026-11.7%

    Nothing announced by GALT that day or the session before.

Share of unusual movement by asset

For each asset, the share of GALT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
belapectin
events and moves
915%
Other company news (earnings, financing, releases naming no asset)—28%
Sessions with no dated event—57%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2/3
Galectin-3Polysaccharide
MASH / NASH
NASH Cirrhosis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 December 2024Topline resultbelapectinNAVIGATE Phase 2b/3 topline results
Galectin Therapeutics · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$2.1M$13M$9.1M-$2.4M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0$2.2M$14M$5.1Mreport ↗
2025-Q3—$2.6M$12M$8.2M-$3.5M operating cash flowreport ↗
2025-Q2—$3.3M$14M$7.5M-$6.6M operating cash flowreport ↗
2025-Q1—$6.5M$7.4M$9.6M-$7.7M operating cash flowreport ↗
2024-Q3—$7.6M$27M$11M-$8.5M operating cash flowreport ↗
2024-Q2—$9.8M$26M$12M-$8.3M operating cash flowreport ↗
2024-Q1—$8.1M$24M$11M-$12M operating cash flowreport ↗
2023-Q3—$7.7M$20M$10M-$7.6M operating cash flowreport ↗
2023-Q2—$7.4M$18M$9.1M-$9.8M operating cash flowreport ↗
2023-Q1—$8.8M$18M$12M-$11M operating cash flowreport ↗
2022-Q3—$6.6M$16M$8.6M-$8.3M operating cash flowreport ↗
2022-Q2—$8.1M$24M$9.6M-$7.4M operating cash flowreport ↗
2022-Q1—$8.1M$32M$9.9M-$8.0M operating cash flowreport ↗
2021-Q3—$6.6M$37M$8.5M-$5.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$14M$18M$7.7M-$24M operating cash flowreport ↗

For FY2025, Galectin Therapeutics did not disclose revenue. R&D spend was $14.29M, down 60.9% YoY from $36.57M in 2024. Cash and equivalents stood at $17.72M, and the company reported a net loss of $30.84M.

Management guided that current cash, including a $10M line of credit from its chairman, is expected to fund planned operations through April 2027. In the belapectin NAVIGATE trial for MASH cirrhosis and portal hypertension, the 2 mg/kg dose reduced varices incidence by 43.2% versus placebo in the intent-to-treat population without reaching statistical significance on the composite endpoint, by 49.3% in the per-protocol population (nominal p=0.04), and by 68.1% in U.S. per-protocol patients (p=0.02); safety was similar across groups with no drug-related serious adverse events. Additional biomarker analyses were reported, abstracts were accepted for EASL 2026 including an oral presentation, and an FDA meeting is planned for Q2 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$37M$15M$12M-$42M operating cash flowreport ↗
2023-FY—$32M$26M$10M-$33M operating cash flowreport ↗
2022-FY—$32M$19M$9.7M-$31M operating cash flowreport ↗
2021-FY—$24M$40M$7.6M-$24M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($65K), 39 sales ($4.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-31Uihlein Richard E · director, 10% ownerOption exercise31,825,235$3.00$95.5MForm 4
2026-07-31Uihlein Richard E · director, 10% ownerOption exercise2,550,932$4.05$10.3MForm 4
2026-07-31Uihlein Richard E · director, 10% ownerOption exercise (derivative)—$95475705.00—Form 4
2026-07-31Uihlein Richard E · director, 10% ownerOption exercise (derivative)—$10331275.00—Form 4
2026-07-14Jamil Khurram · Chief Medical OfficerOption exercise16,250$3.04$49KForm 4
2026-07-14Jamil Khurram · Chief Medical OfficerOpen-market sale16,250$5.13$83KForm 4
2026-07-14Jamil Khurram · Chief Medical OfficerOption exercise (derivative)16,250——Form 4
2026-06-29Shlevin Harold H. · directorOption exercise22,268$1.23$27KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 98 reporting institutions held 13.9M shares ($37.8M, 13.8% of shares outstanding).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC1,966,542$5.5M
2MARSHALL WACE, LLP1,219,912$3.4M
3OSAIC HOLDINGS, INC.1,122,670$3.1M
4BlackRock, Inc.799,237$2.2M
5MILLENNIUM MANAGEMENT LLC798,434$2.2M
6Wealthspire Advisors, LLC721,788$2.0M
7GEODE CAPITAL MANAGEMENT, LLC612,786$1.7M
8SUSQUEHANNA INTERNATIONAL GROUP, LLP555,702$1.6M
9TWO SIGMA INVESTMENTS, LP467,063$1.3M
10COMMONWEALTH EQUITY SERVICES, LLC367,113$1.0M
11VANGUARD FIDUCIARY TRUST CO304,241$849K
12CITADEL ADVISORS LLC290,360$810K
13LPL Financial LLC267,200$745K
14Vivaldi Capital Management LP258,584$721K
15STATE STREET CORP258,432$721K